Inside the Cockpit

Gunjan Bhardwaj

The modern system of drug discovery and development is broken. Development costs are so high that pharmaceutical companies can only afford to develop blockbuster drugs that will be worth at least $1 billion annually and take a decade to come to market. Researchers have incentives to hide their work rather than collaborate. And the most valuable data for drug discovery is hidden in silos or unpublished research. Entrepreneur Gunjan Bhardwaj, CEO of Innoplexus and Cancercoin, is pioneering a new paradigm to bring drug development to meet the moral imperative of bringing lifesaving drugs to market faster and cheaper. His innovative combination of blockchain technology and second- and third-wave artificial intelligence changes the incentives for all the players in the drug development ecosystem. The broken drug development system exacts an enormous toll of human pain and suffering. Fixing it is a moral imperative. Inside the Cockpit shows how.

Gunjan Bhardwaj

An India-born German citizen, Dr. Gunjan Bhardwaj holds a doctorate from the European Business School in Germany, an MBA in management and marketing from Pforzheim Graduate School, and a bachelor’s from Indian Institute of Technology, Bombay. The founder and CEO of Innoplexus AG, he is the author or co-author of twenty-three patent applications and has spoken and published worldwide on innovation, artificial intelligence, marketing, and drug development. Gunjan currently serves on multiple advisory boards, including the Centre for Human and Machine Intelligence and the Forbes Technology Council. He lives in Germany.

More Lioncrest Work

View All Books